Bench International Appoints Jim Lang to Halozyme Therapeutics Board, Enhancing Drug Delivery Expertise
Bench International has made a significant move by appointing Jim Lang to the Board of Directors of Halozyme Therapeutics, Inc., a company that is making strides in the biopharmaceutical industry. Halozyme is known for its revolutionary drug delivery technologies, which aim to enhance the way medicines are administered to patients globally. With this strategic appointment, Bench International is not only reinforcing Halozyme's board but also aligning it with its trajectory of innovation and global collaboration.
Jim Lang brings a wealth of experience in scaling life sciences organizations and has extensive governance oversight experience in public companies that navigate complex regulatory landscapes. His current board memberships at OptimizeRx Corp. and BioVie Inc. add to his credentials, making him a well-rounded choice for Halozyme's strategic goals. His history in nurturing enterprise growth and facilitating significant partnerships is particularly relevant as Halozyme continues to evolve.
"Jim Lang's rare combination of public-company board experience, expertise in strategic scaling, and a deep understanding of the life sciences ecosystem makes him an exceptional addition to our board," expressed Denise (DeeDee) DeMan, the Founder, Chairman, and CEO of Bench International. This appointment not only showcases the commitment of Bench International to enhance corporate governance at Halozyme but also signals their belief in the company's potential to lead in drug delivery innovation.
Matthew L. Posard, Chairman of Halozyme's Nominating and Governance Committee, shared his appreciation for Bench's work in identifying Lang, highlighting the dedication and professionalism that led to this successful outcome. He noted that this move aligns with Halozyme's ongoing focus on robust governance and board leadership.
As Halozyme advances its strategic priorities, it also emphasizes the significance of strong partnerships with leading pharmaceutical companies. This appointment is poised to bolster the company's governance structure and further its influence in the dynamic life sciences field. The synergy between Lang's expertise and Halozyme's goals reflects a promising future for both the company and its clientele.
Bench International has been a cornerstone in executive search, recruiting, and leadership advisory services exclusively for the life sciences sector for over 50 years. With successes that include facilitating $172 billion in client exits and maintaining a remarkable 98% project completion rate, it has established a reputation for building transformative boards and guiding leadership teams through periods of change and growth. The firm focuses on not merely filling positions but ensuring that the leadership they provide has a long-term impact on client organizations.
With services such as Talent Mapping and Gap Analyses, Bench also offers interim leadership solutions to help its clients with their evolving needs.
In conclusion, the addition of Jim Lang to Halozyme Therapeutics' Board of Directors illustrates a strategic effort to enhance the board's capabilities and to align with the demands of a rapidly changing medical landscape. It signifies not only a commitment to governance but also to the advancement of innovative drug delivery solutions that can reshape patient care worldwide.
In a constantly evolving global health environment, such appointments are crucial for companies seeking to maintain relevance and drive meaningful change in their respective fields. Readers can learn more about Bench International's impact on the life sciences industry at their official website, www.benchinternational.com.
Jim Lang brings a wealth of experience in scaling life sciences organizations and has extensive governance oversight experience in public companies that navigate complex regulatory landscapes. His current board memberships at OptimizeRx Corp. and BioVie Inc. add to his credentials, making him a well-rounded choice for Halozyme's strategic goals. His history in nurturing enterprise growth and facilitating significant partnerships is particularly relevant as Halozyme continues to evolve.
"Jim Lang's rare combination of public-company board experience, expertise in strategic scaling, and a deep understanding of the life sciences ecosystem makes him an exceptional addition to our board," expressed Denise (DeeDee) DeMan, the Founder, Chairman, and CEO of Bench International. This appointment not only showcases the commitment of Bench International to enhance corporate governance at Halozyme but also signals their belief in the company's potential to lead in drug delivery innovation.
Matthew L. Posard, Chairman of Halozyme's Nominating and Governance Committee, shared his appreciation for Bench's work in identifying Lang, highlighting the dedication and professionalism that led to this successful outcome. He noted that this move aligns with Halozyme's ongoing focus on robust governance and board leadership.
As Halozyme advances its strategic priorities, it also emphasizes the significance of strong partnerships with leading pharmaceutical companies. This appointment is poised to bolster the company's governance structure and further its influence in the dynamic life sciences field. The synergy between Lang's expertise and Halozyme's goals reflects a promising future for both the company and its clientele.
Bench International has been a cornerstone in executive search, recruiting, and leadership advisory services exclusively for the life sciences sector for over 50 years. With successes that include facilitating $172 billion in client exits and maintaining a remarkable 98% project completion rate, it has established a reputation for building transformative boards and guiding leadership teams through periods of change and growth. The firm focuses on not merely filling positions but ensuring that the leadership they provide has a long-term impact on client organizations.
With services such as Talent Mapping and Gap Analyses, Bench also offers interim leadership solutions to help its clients with their evolving needs.
In conclusion, the addition of Jim Lang to Halozyme Therapeutics' Board of Directors illustrates a strategic effort to enhance the board's capabilities and to align with the demands of a rapidly changing medical landscape. It signifies not only a commitment to governance but also to the advancement of innovative drug delivery solutions that can reshape patient care worldwide.
In a constantly evolving global health environment, such appointments are crucial for companies seeking to maintain relevance and drive meaningful change in their respective fields. Readers can learn more about Bench International's impact on the life sciences industry at their official website, www.benchinternational.com.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.